Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Hospital waste water: health risk for human and environment by cytostatic drug emissions? Part I: Model calculation and chemical monitoring

  • 1,
  • 1, 2,
  • 1,
  • 1,
  • 2,
  • 2,
  • 1,
  • 1,
  • 3,
  • 2,
  • 2 and
  • 2Email author
BMC Pharmacology20077 (Suppl 2) :A69

https://doi.org/10.1186/1471-2210-7-S2-A69

  • Published:

Keywords

  • Doxorubicin
  • Carboplatin
  • Solid Phase Extraction
  • Oxaliplatin
  • Epirubicin

Project

"Chemical analysis, risk assessment and elimination of selected cytostatic agents from hospital waste water", performed at the University Hospital (AKH) Vienna.

Methods

Drugs: 5-fluorouracil, doxorubicin, epirubicin, daunorubicin, cisplatin, carboplatin, oxaliplatin. Model calculation: Minimum, maximum annual average concentrations and cumulative amount in hospital sewage were calculated. Parameters: drug, water consumption in the oncologic in-patient treatment ward, renal human excretion rate. Chemical analysis: platinum compounds: ICP-MS (speciation analysis by on-line coupling of HPLC to ICP-MS), limits of detection: cisplatin (0.09 μg/l), carboplatin (0.1 μg/l), oxaliplatin (0.15 μg/l). Anthracyclines: solid phase extraction, HPLC and fluorescence detection (FLD), limits of detection: doxorubicin (0.05 μg/l), daunorubicin (0.06 μg/l). 5-Fluorouracil: solid phase extraction, capillary electrophoresis, limit of detection 1.7 μg/l. Chemical monitoring: waste water samples: effluent of (a) the total hospital (TH), (b) the oncological ward (OW), collected before dilution in the Vienna sewer system for a total period of 98 days.

Results

Pt concentrations ranged from 3.2 to 266 μg/l; estimates revealed that about one third of the administered drugs was detected in the waste water of the oncologic ward. 5-Fluorouracil was detected in waste water up to 124 μg/l, doxorubicin up to 1.35 μg/l. The concentrations determined chemically agreed with the predictions based upon model calculations.

Authors’ Affiliations

(1)
BOKU University of Natural Resources and Applied Life Sciences, Vienna, Austria
(2)
Institute of Cancer Research, Clinics of Internal Medicine I, Medical University of Vienna, Austria
(3)
Umweltbundesamt, Vienna, Austria

Copyright

© Fuerhacker et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.

Advertisement